Next Article in Journal
Why Venous Leg Ulcers Have Difficulty Healing: Overview on Pathophysiology, Clinical Consequences, and Treatment
Previous Article in Journal
Changes in Cellular Regulatory Factors before and after Decompression of Odontogenic Keratocysts
Article

Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study

1
Department of Infectious Diseases and Neuroinfections, Medical University of Białystok, 15-085 Białystok, Poland
2
Department of Infectious Diseases, Jan Kochanowski University, 25-369 Kielce, Poland
3
Department of Infectious Diseases and Hepatology, Medical University of Lublin, 20-059 Lublin, Poland
4
Department of Forensic Medicine, Wrocław Medical University, 50-367 Wrocław, Poland
5
First Infectious Diseases Ward, Gromkowski Regional Specialist Hospital in Wrocław, 51-149 Wrocław, Poland
6
Department of Tropical Medicine and Epidemiology, Medical University of Gdańsk, 80-210 Gdańsk, Poland
7
Department of Infectious Diseases, University of Medical Sciences, 61-701 Poznań, Poland
8
Department of Infectious Diseases, Medical University of Gdańsk, 80-210 Gdańsk, Poland
9
Department of Infectious Diseases and Allergology, Military Institute of Medicine, 04-141 Warsaw, Poland
10
Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 87-100 Torun, Poland
11
Department of Infectious Diseases in Bytom, Medical University of Silesia, 40-055 Katowice, Poland
12
Department of Infectious Diseases and Hepatology, Wrocław Medical University, 50-367 Wrocław, Poland
13
Department of Infectious Diseases, Liver Diseases and Acquired Immune Deficiencies, Wrocław Medical University, 50-367 Wrocław, Poland
14
Department of Infectious Diseases and Child Neurology, Poznan University of Medical Sciences, 61-701 Poznań, Poland
15
Department of Infectious Diseases and Hepatology, Medical University of Białystok, 15-089 Białystok, Poland
16
Department of Pediatrics and Infectious Diseases, Wrocław Medical University, 50-367 Wrocław, Poland
*
Author to whom correspondence should be addressed.
Anna Moniuszko-Malinowska and Piotr Czupryna contributed equally to the manuscript.
J. Clin. Med. 2021, 10(1), 28; https://doi.org/10.3390/jcm10010028
Received: 2 December 2020 / Revised: 17 December 2020 / Accepted: 21 December 2020 / Published: 24 December 2020
(This article belongs to the Section Hematology)
Because the optimal treatment for COVID-19 is still unknown, it is important to explore every potential way of improving the chances of survival for COVID-19 patients. The aim of the study was to analyze the effectiveness of convalescent plasma on COVID-19 patients. The study population consisted of 78 patients diagnosed with COVID-19, selected from the SARSTer national database, who received convalescent plasma. The impact on clinical and laboratory parameters was assessed. A clinical improvement was observed in 62 (79%) patients, and 10 (13%) patients died from COVID-19. No side effects of the convalescent plasma treatment were observed. When plasma was administered earlier than 7 days from diagnosis, the total hospitalization time was shorter (p < 0.05). Plasma efficacy was inferior to remdesivir in endpoints such as the necessity and duration of oxygen therapy, the duration of hospitalization, and mortality rate, and inferior to other drugs in the case of the duration of hospitalization and the necessity of constant oxygen therapy, but comparable in most other measured endpoints. A comparison of a 30-day mortality rate in patients who received plasma and remdesivir (4/25, 16%) and who received only plasma (6/53, 11%) showed no significant difference. Convalescent plasma efficacy is inferior to remdesivir when treating COVID-19 patients but the addition of remdesivir to plasma does not improve the treatment effectiveness. In most endpoints, plasma was comparable to other treatment options. In our opinion, convalescent plasma may be used as a supportive treatment in COVID-19 patients because of the low frequency of adverse effects and availability, but must be given as early from the diagnosis as possible. View Full-Text
Keywords: convalescent plasma; COVID-19; transfusion convalescent plasma; COVID-19; transfusion
Show Figures

Figure 1

MDPI and ACS Style

Moniuszko-Malinowska, A.; Czupryna, P.; Zarębska-Michaluk, D.; Tomasiewicz, K.; Pancewicz, S.; Rorat, M.; Dworzańska, A.; Sikorska, K.; Bolewska, B.; Lorenc, B.; Chciałowski, A.; Kozielewicz, D.; Oczko-Grzesik, B.; Szymanek-Pasternak, A.; Szetela, B.; Figlerowicz, M.; Rogalska, M.; Zaleska, I.; Flisiak, R. Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study. J. Clin. Med. 2021, 10, 28. https://doi.org/10.3390/jcm10010028

AMA Style

Moniuszko-Malinowska A, Czupryna P, Zarębska-Michaluk D, Tomasiewicz K, Pancewicz S, Rorat M, Dworzańska A, Sikorska K, Bolewska B, Lorenc B, Chciałowski A, Kozielewicz D, Oczko-Grzesik B, Szymanek-Pasternak A, Szetela B, Figlerowicz M, Rogalska M, Zaleska I, Flisiak R. Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study. Journal of Clinical Medicine. 2021; 10(1):28. https://doi.org/10.3390/jcm10010028

Chicago/Turabian Style

Moniuszko-Malinowska, Anna, Piotr Czupryna, Dorota Zarębska-Michaluk, Krzysztof Tomasiewicz, Sławomir Pancewicz, Marta Rorat, Anna Dworzańska, Katarzyna Sikorska, Beata Bolewska, Beata Lorenc, Andrzej Chciałowski, Dorota Kozielewicz, Barbara Oczko-Grzesik, Anna Szymanek-Pasternak, Bartosz Szetela, Magdalena Figlerowicz, Magdalena Rogalska, Izabela Zaleska, and Robert Flisiak. 2021. "Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study" Journal of Clinical Medicine 10, no. 1: 28. https://doi.org/10.3390/jcm10010028

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop